A Case of Pulmonary Embolism with Sarcomatoid Malignant Pleural Mesothelioma with Long-Term Pleural Effusion

References

• Beckett P, Edwards J, Fennell D, Hubbard R, Woolhouse I, Peake MD. Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales. Lung Cancer. 2015;88(3):344–348. doi:10.1016/j.lungcan.2015.03.005
   PubMed Web of Science ®Google Scholar
• Soeberg MJ, Leigh J, van Zandwijk N. Malignant mesothelioma in Australia 2015: current incidence and asbestos exposure trends. J Toxicol Environ Health B Crit Rev. 2016;19(5–6):173–189. doi:10.1080/10937404.2016.1194254
   PubMed Web of Science ®Google Scholar
• Scherpereel A, Astoul P, Baas P, et al. [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma]. Zhongguo Fei Ai Za Zhi = Chinese J Lung Cancer. 2010;13(10):C23–45. [Chinese]. doi:10.3779/j.issn.1009-3419.2010.10.14
   PubMedGoogle Scholar
• Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003;8(4):381–388. doi:10.1634/theoncologist.8-4-381
   PubMed Web of Science ®Google Scholar
• Rudd RM. Malignant mesothelioma. Br Med Bull. 2010;93:105–123. doi:10.1093/bmb/ldp047
   PubMed Web of Science ®Google Scholar
• Mazurek JM, Syamlal G, Wood JM, Hendricks SA, Weston A. Malignant mesothelioma mortality - United States, 1999–2015. MMWR Morb Mortal Wkly Rep. 2017;66(8):214–218. doi:10.15585/mmwr.mm6608a3
   PubMed Web of Science ®Google Scholar
• Lacourt A, Gramond C, Rolland P, et al. Occupational and non-occupational attributable risk of asbestos exposure for malignant pleural mesothelioma. Thorax. 2014;69(6):532–539. doi:10.1136/thoraxjnl-2013-203744
   PubMed Web of Science ®Google Scholar
• Astoul P, Roca E, Galateau-Salle F, Scherpereel A. Malignant pleural mesothelioma: from the bench to the bedside. Respiration. 2012;83(6):481–493. doi:10.1159/000339259
   PubMed Web of Science ®Google Scholar
• Guo Z, Carbone M, Zhang X, et al. Improving the accuracy of mesothelioma diagnosis in China. J Thorac Oncol. 2017;12(4):714–723. doi:10.1016/j.jtho.2016.12.006
   PubMed Web of Science ®Google Scholar
• British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax. 2007;62(Suppl 2):ii1–ii19. doi:10.1136/thx.2007.087619
   PubMedGoogle Scholar
• Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3):479–495. doi:10.1183/09031936.00063109
   PubMed Web of Science ®Google Scholar
• Marchevsky AM, LeStang N, Hiroshima K, et al. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. Hum Pathol. 2017;67:160–168. doi:10.1016/j.humpath.2017.07.015
   PubMed Web of Science ®Google Scholar
• Liu M, Cui A, Zhai ZG, et al. Incidence of pleural effusion in patients with pulmonary embolism. Chin Med J. 2015;128(8):1032–1036. doi:10.4103/0366-6999.155073
   PubMed Web of Science ®Google Scholar
• Koksal D, Safak O, Ozcan A, Agackiran Y, Erturk H, Findik G. Thromboembolic events in malignant pleural mesothelioma. Clin Appl Thromb Hemost. 2016;22(4):390–394. doi:10.1177/1076029614564861
   PubMed Web of Science ®Google Scholar
• Nakano T, Chahinian AP, Shinjo M, et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer. 1998;77(6):907–912. doi:10.1038/bjc.1998.150
   PubMed Web of Science ®Google Scholar
• Idell S, Pueblitz S, Emri S, et al. Regulation of fibrin deposition by malignant mesothelioma. Am J Pathol. 1995;147(5):1318–1329.
   PubMed Web of Science ®Google Scholar
• Migliore M. Efficacy and safety of single-trocar technique for minimally invasive surgery of the chest in the treatment of noncomplex pleural disease. J Thorac Cardiovasc Surg. 2003;126(5):1618–1623. doi:10.1016/S0022-5223(03)00592-0
   PubMed Web of Science ®Google Scholar
• Migliore M, Giuliano R, Aziz T, Saad RA, Sgalambro F. Four-step local anesthesia and sedation for thoracoscopic diagnosis and management of pleural diseases. Chest. 2002;121(6):2032–2035. doi:10.1378/chest.121.6.2032
   PubMed Web of Science ®Google Scholar
• Froudarakis ME. Diagnostic work-up of pleural effusions. Respiration. 2008;75(1):4–13. doi:10.1159/000112221
   PubMed Web of Science ®Google Scholar
• Kindler HL, Ismaila N, Armato SG, et al. Treatment of malignant pleural mesothelioma: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(13):1343–1373. doi:10.1200/JCO.2017.76.6394
   PubMed Web of Science ®Google Scholar
• Kitajima K, Doi H, Kuribayashi K. Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma. Jpn J Radiol. 2016;34(8):537–547. doi:10.1007/s11604-016-0555-1
   PubMed Web of Science ®Google Scholar
• Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol. 2010;23(3):470–479. doi:10.1038/modpathol.2009.180
   PubMed Web of Science ®Google Scholar
• Lucas DR, Pass HI, Madan SK, et al. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology. 2003;42(3):270–279. doi:10.1046/j.1365-2559.2003.01583.x
   PubMed Web of Science ®Google Scholar
• Eguchi T, Kadota K, Mayor M, et al. Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. Oncotarget. 2017;8(44):77872–77882. doi:10.18632/oncotarget.20845
   PubMedGoogle Scholar
• Zauderer MG, Tsao AS, Dao T, et al. A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma. Clin Cancer Res. 2017;23(24):7483–7489. doi:10.1158/1078-0432.CCR-17-2169
   PubMed Web of Science ®Google Scholar
• Berg KB, Churg A. GATA3 immunohistochemistry for distinguishing sarcomatoid and desmoplastic mesothelioma from sarcomatoid carcinoma of the lung. Am J Surg Pathol. 2017;41(9):1221–1225. doi:10.1097/PAS.0000000000000825
   PubMed Web of Science ®Google Scholar
• Kriegsmann K, Cremer M, Zgorzelski C, et al. Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer. Pathology. 2019;51(3):240–245. doi:10.1016/j.pathol.2018.11.009
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644. doi:10.1200/JCO.2003.11.136-8
   PubMed Web of Science ®Google Scholar
• Wald O, Sugarbaker DJ. New concepts in the treatment of malignant pleural mesothelioma. Annu Rev Med. 2018;69:365–377. doi:10.1146/annurev-med-041316-085813
   PubMed Web of Science ®Google Scholar
• Bertoglio P, Waller DA. The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidence. Expert Rev Respir Med. 2016;10(6):663–672. doi:10.1586/17476348.2016.1171147
   PubMed Web of Science ®Google Scholar
• Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763–772. doi:10.1016/S1470-2045(11)70149-8
   PubMed Web of Science ®Google Scholar
• Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J. 2010;36(6):1362–1369. doi:10.1183/09031936.00039510
   PubMed Web of Science ®Google Scholar
• Cao C, Tian D, Manganas C, Matthews P, Yan TD. Systematic review of trimodality therapy for patients with malignant pleural mesothelioma. Ann Cardiothorac Surg. 2012;1(4):428–437. doi:10.3978/j.issn.2225-319X.2012.11.07
   PubMedGoogle Scholar
• Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(18):3007–3013. doi:10.1200/JCO.2008.20.3943
   PubMed Web of Science ®Google Scholar